TC-I 15CAS# 916734-43-5 |
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 916734-43-5 | SDF | Download SDF |
| PubChem ID | 90488948 | Appearance | Powder |
| Formula | C23H28N4O6S2 | M.Wt | 520.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 25 mM in 1.1eq. NaOH | ||
| Chemical Name | (2S)-2-[[(4R)-3-(benzenesulfonyl)-5,5-dimethyl-1,3-thiazolidine-4-carbonyl]amino]-3-(benzylcarbamoylamino)propanoic acid | ||
| SMILES | CC1(C(N(CS1)S(=O)(=O)C2=CC=CC=C2)C(=O)NC(CNC(=O)NCC3=CC=CC=C3)C(=O)O)C | ||
| Standard InChIKey | XKLHCUGVLCGKKX-RBUKOAKNSA-N | ||
| Standard InChI | InChI=1S/C23H28N4O6S2/c1-23(2)19(27(15-34-23)35(32,33)17-11-7-4-8-12-17)20(28)26-18(21(29)30)14-25-22(31)24-13-16-9-5-3-6-10-16/h3-12,18-19H,13-15H2,1-2H3,(H,26,28)(H,29,30)(H2,24,25,31)/t18-,19+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent α2β1 integrin inhibitor (IC50 values for the inhibition of human platelet adhesion to type I collagen are 12 and 715 nM for platelets under static conditions and under flow, respectively). Displays selectivity for α2β1 over αvβ3, α5β1, α6β1 and αIIbβ3 at concentrations exceeding 1000 nM. Reduces collagen IV production in mesangial cells. Active in vivo; prevents ferric chloride-induced clot formation in mice. |
TC-I 15 Dilution Calculator
TC-I 15 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9208 mL | 9.6039 mL | 19.2079 mL | 38.4157 mL | 48.0197 mL |
| 5 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL | 7.6831 mL | 9.6039 mL |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL | 3.8416 mL | 4.802 mL |
| 50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.7683 mL | 0.9604 mL |
| 100 mM | 0.0192 mL | 0.096 mL | 0.1921 mL | 0.3842 mL | 0.4802 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Clematiunicinoside E
Catalog No.:BCN7809
CAS No.:916649-92-8
- Clematomandshurica saponin B
Catalog No.:BCN7810
CAS No.:916649-91-7
- Coriatin
Catalog No.:BCN4457
CAS No.:91653-75-7
- Zingiberen newsaponin
Catalog No.:BCN2942
CAS No.:91653-50-8
- Senkyunolide C
Catalog No.:BCC9141
CAS No.:91652-78-7
- Clinodiside A
Catalog No.:BCN1048
CAS No.:916347-31-4
- Acetylvirolin
Catalog No.:BCN7041
CAS No.:916264-22-7
- Gopherenediol
Catalog No.:BCN6582
CAS No.:916236-79-8
- AC 55541
Catalog No.:BCC3951
CAS No.:916170-19-9
- TCS 1102
Catalog No.:BCC4063
CAS No.:916141-36-1
- Benidipine HCl
Catalog No.:BCC4395
CAS No.:91599-74-5
- Momordicine I
Catalog No.:BCN3058
CAS No.:91590-76-0
- 5,7,4'-Trihydroxy-8-methylflavanone
Catalog No.:BCN2844
CAS No.:916917-28-7
- Enniatin B
Catalog No.:BCN4774
CAS No.:917-13-5
- 2-[(Acetylthio)methyl]-phenylpropionic acid
Catalog No.:BCC8507
CAS No.:91702-98-6
- CYT997 (Lexibulin)
Catalog No.:BCC4601
CAS No.:917111-44-5
- Bromfenac Sodium
Catalog No.:BCC4641
CAS No.:91714-93-1
- MPC 6827 hydrochloride
Catalog No.:BCC8040
CAS No.:917369-31-4
- Letermovir
Catalog No.:BCC1700
CAS No.:917389-32-3
- Cyclo(Ile-Leu)
Catalog No.:BCN2434
CAS No.:91741-17-2
- Platycoside M1
Catalog No.:BCN3238
CAS No.:917482-67-8
- Platycoside M3
Catalog No.:BCN3243
CAS No.:917482-69-0
- PSB 0474
Catalog No.:BCC7459
CAS No.:917567-60-3
- CCMI
Catalog No.:BCC7788
CAS No.:917837-54-8
Inhibition of integrin alpha2beta1 ameliorates glomerular injury.[Pubmed:22440900]
J Am Soc Nephrol. 2012 Jun;23(6):1027-38.
Mesangial cells and podocytes express integrins alpha1beta1 and alpha2beta1, which are the two major collagen receptors that regulate multiple cellular functions, including extracellular matrix homeostasis. Integrin alpha1beta1 protects from glomerular injury by negatively regulating collagen production, but the role of integrin alpha2beta1 in renal injury is unclear. Here, we subjected wild-type and integrin alpha2-null mice to injury with adriamycin or partial renal ablation. In both of these models, integrin alpha2-null mice developed significantly less proteinuria and glomerulosclerosis. In addition, selective pharmacological inhibition of integrin alpha2beta1 significantly reduced adriamycin-induced proteinuria, glomerular injury, and collagen deposition in wild-type mice. This inhibitor significantly reduced collagen synthesis in wild-type, but not integrin alpha2-null, mesangial cells in vitro, demonstrating that its effects are integrin alpha2beta1-dependent. Taken together, these results indicate that integrin alpha2beta1 contributes to glomerular injury by positively regulating collagen synthesis and suggest that its inhibition may be a promising strategy to reduce glomerular injury and proteinuria.
Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism.[Pubmed:19141632]
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):719-24.
There is a grave need for safer antiplatelet therapeutics to prevent heart attack and stroke. Agents targeting the interaction of platelets with the diseased vessel wall could impact vascular disease with minimal effects on normal hemostasis. We targeted integrin alpha(2)beta(1), a collagen receptor, because its overexpression is associated with pathological clot formation whereas its absence does not cause severe bleeding. Structure-activity studies led to highly potent and selective small-molecule inhibitors. Responses of integrin alpha(2)beta(1) mutants to these compounds are consistent with a computational model of their mode of inhibition and shed light on the activation mechanism of I-domain-containing integrins. A potent compound was proven efficacious in an animal model of arterial thrombosis, which demonstrates in vivo efficacy for inhibition of this platelet receptor. These results suggest that targeting integrin alpha(2)beta(1) could be a potentially safe, effective approach to long-term therapy for cardiovascular disease.
